Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


April 25, 2015 3:27 PM ET

Healthcare Equipment and Supplies

Company Overview of LVB Acquisition, Inc.

Company Overview

LVB Acquisition, Inc. through its subsidiary Biomet Inc., manufactures and distributes surgical products. The company was incorporated in 2006 and is based in Wilmington, Delaware.

1209 Orange Street

Corporation Trust Center

Wilmington, DE 19801

United States

Founded in 2006

Phone:

212-750-8300

Key Executives for LVB Acquisition, Inc.

Chief Executive Officer, President and Director
Age: 51
Chief Financial Officer, Principal Accounting Officer and Senior Vice President
Age: 50
Senior Vice President of World Wide Operations
Age: 53
Senior Vice President and President of Biomet - Europe Middle East & Africa
Age: 57
Senior Vice President, Group President of Spine, Microfixation & Bone Healing, President of EBI LLC and President of Biomet Microfixation LLC
Age: 37
Compensation as of Fiscal Year 2014.

LVB Acquisition, Inc. Key Developments

LVB Acquisition, Inc. and Biomet, Inc. Announces Board Changes

On February 14, 2014, Michael Dal Bello resigned from the Board of Directors, the Audit Committee of the Board of Directors and Compensation Committee of the Board of Directors of each of LVB Acquisition, Inc. and Biomet, Inc. Mr. Dal Bello did not resign in connection with any disagreement with the company or its management. Effective on February 14, 2014, the Board of Directors appointed Timur Akazhanov as a director to serve out Mr. Dal Bello's term. Mr. Akazhanov is an Associate at The Blackstone Group. Dal Bello had been previously designated by Blackstone to serve on the company's Board of Directors and Blackstone has notified the company that it is designating Mr. Akazhanov to fill the vacancy resulting from Mr. Dal Bello's resignation. On February 14, 2014, J. Pat Richardson resigned his position as Vice President and Corporate Controller in order to become the Company's Vice President, Investor Relations. In connection with this transition, Mr. Richardson resigned from his position as principal accounting officer. Also on February 14, 2014, the company designated Daniel P. Florin as the company's principal accounting officer. Mr. Florin has been Senior Vice President and Chief Financial Officer of the company since June 2007. Prior thereto, Mr. Florin served as Vice President and Corporate Controller for Boston Scientific Corporation since 2001. Prior to being appointed as Corporate Controller in 2001, Mr. Florin served in financial leadership positions within Boston Scientific Corporation and its various business units since July 1995 and was with C. R. Bard from October 1990 through June 1995.

LVB Acquisition, Inc. and Biomet Inc. Enter Incremental Term Facility Amendment

On September 25, 2013, LVB Acquisition, Inc., Biomet, Inc. and certain of Biomet's subsidiaries entered into an incremental term facility amendment and an amendment to Biomet's senior secured credit facilities with the other loan parties party thereto and Bank of America, N.A., as the additional term lender. The Amendments were entered into pursuant to that certain Credit Agreement, dated as of September 25, 2007, as amended and restated by that certain Amendment and Restatement Agreement dated as of August 2, 2012, by and among Biomet, LVB, certain subsidiaries of Biomet, Bank of America, N.A., as Administrative Agent, Swing Line Lender and L/C Issuer and each lender from time to time party thereto. By entering into the Amendments, the additional term lender party thereto has agreed to provide additional dollar-denominated term loans in aggregate principal amount of approximately $870.5 million, which will be used to refinance a portion of the term loans outstanding under the Credit Agreement due on July 25, 2017. The other material terms of the Additional Term Loans, which will mature on July 25, 2017, are identical to the term loans that were refinanced. In addition, the Amendments provide for a reduction in the interest rate margin applicable to the extended Dollar term loans outstanding under the Credit Agreement from 3.75% per annum to 3.50% for LIBOR loans and 2.75% per annum to 2.50% for base rate loans. In connection with the Amendments, Biomet is required to pay an upfront fee of 0.25% of the aggregate amount of the Additional Term Loans and the extended Dollar term loans as of the effective date of the Amendments.

Similar Private Companies By Industry

Company Name Region
PlainSense Wheelchairs, Inc. United States
Benedict Optical, Inc. United States
A.R. Nelson Co. Inc. United States
Shepard Medical Products, Inc. United States
Biosense Webster, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LVB Acquisition, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.